LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients.

    Obeid, Karam M / Sapkota, Smarika / Cao, Qing / Richmond, Steven / Watson, Allison P / Karadag, Fatma Keklik / Young, Jo-Anne H / Pruett, Timothy / Weisdorf, Daniel J / Ustun, Celalettin

    Transplant infectious disease : an official journal of the Transplantation Society

    2021  Volume 24, Issue 1, Page(s) e13720

    Abstract: Background: Clostridioides difficile infection (CDI) frequently complicates allogeneic hematopoietic stem cell (allo-HCT) and solid organ transplantation (SOT).: Methods: We retrospectively analyzed risk factors and outcomes of CDI occurring within ... ...

    Abstract Background: Clostridioides difficile infection (CDI) frequently complicates allogeneic hematopoietic stem cell (allo-HCT) and solid organ transplantation (SOT).
    Methods: We retrospectively analyzed risk factors and outcomes of CDI occurring within 30 days of transplant.
    Results: Between March 2010 and June 2015, 466 allo-HCT and 1454 SOT were performed. The CDI cumulative incidence (95% CI) was 10% (8-13) and 4% (3-5), following allo-HCT and SOT, respectively (p < .01), occurring at a median (range) 7.5 days (1-30) and 11 (1-30), respectively (p = .18). In multivariate analysis, fluoroquinolones use within 14 days pre-transplantation was a risk factor for CDI following allo-HCT (HR 4.06 [95% CI 1.31-12.63], p = .02), and thoracic organ(s) transplantation was a risk factor for CDI following SOT (HR 3.03 [95% CI 1.31-6.98]) for lung and 3.90 (1.58-9.63) for heart and heart/kidney transplant, p = .02. Compared with no-CDI patients, the length of stay (LOS) was prolonged in both allo-HCT (35 days [19-141] vs. 29 [13-164], p < .01) and SOT with CDI (16.5 [4-101] vs. 7 [0-159], p < .01), though not directly attributed to CDI. In allo-HCT, severe acute graft-versus-host disease (aGVHD) occurred more frequently in patients with CDI (33.3% vs. 15.8% without CDI, p = .01) and most aGVHD (87.5%) followed CDI. Non-relapse mortality or overall survival, not attributed to CDI, were also similar in both allo-HCT and SOT.
    Conclusions: Early post-transplant CDI is frequent, associated with fluoroquinolones use in allo-HCT and the transplanted organ in SOT, and is associated with longer LOS in both the groups without difference in survival but with increased aGVHD in allo-HCT.
    MeSH term(s) Clostridioides difficile ; Clostridium Infections/epidemiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cells ; Humans ; Organ Transplantation/adverse effects ; Retrospective Studies ; Transplant Recipients
    Language English
    Publishing date 2021-09-25
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 1476094-0
    ISSN 1399-3062 ; 1398-2273
    ISSN (online) 1399-3062
    ISSN 1398-2273
    DOI 10.1111/tid.13720
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hypoxia-Inducible Factor 1α and AT-Rich Interactive Domain-Containing Protein 1A Expression in Pituitary Adenomas: Association with Pathological, Clinical, and Radiological Features.

    Kinali, Burak / Senoglu, Mehmet / Karadag, Fatma Keklik / Karadag, Ali / Middlebrooks, Erik H / Oksuz, Pinar / Sandal, Evren / Turk, Caglar / Diniz, Gülden

    World neurosurgery

    2018  Volume 121, Page(s) e716–e722

    Abstract: Background: Hypoxia-inducible factor (HIF) plays a major role in tumorigenesis and cancer progression. In hypoxic conditions, HIF is upregulated and has been shown to activate multiple genes required for cells to adapt to hypoxia. AT-rich interactive ... ...

    Abstract Background: Hypoxia-inducible factor (HIF) plays a major role in tumorigenesis and cancer progression. In hypoxic conditions, HIF is upregulated and has been shown to activate multiple genes required for cells to adapt to hypoxia. AT-rich interactive domain-containing protein 1A (ARID1A), a SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling gene has context-dependent tumor-suppressive and oncogenic roles in cancer. We assessed the correlations between the expression and mutations of HIF1A and ARID1A in histopathologically confirmed pituitary adenomas.
    Methods: We performed a retrospective analysis of 71 patients who had undergone surgery for pituitary adenoma. Patient demographic, radiological, and histopathological features were correlated with HIF1A and ARID1A expression.
    Results: Most cases were HIF1A positive (62%). No significant correlation was found between HIF1A expression and age, gender, tumor size, bone erosion, hemorrhage, or Ki-67 index. An inverse correlation was demonstrated between HIF1A and cavernous sinus invasion (P = 0.035). ARID1A loss was found in 28.2% of pituitary adenomas. No significant correlation was found between ARID1A and any of the assessed variables.
    Conclusions: In our patient cohort, we found that most pituitary adenomas expressed HIF1A. To the best of our knowledge, we are the first to assess the presence of ARID1A loss in pituitary adenomas, which occurred in 28.2% of cases. No individual demographic, imaging, or histopathological feature was predictive of ARID1A. Likewise, with the exception of an increased incidence of cavernous sinus invasion, no correlation was found with HIF1A. Given the prognostic value of these markers in other malignancies, their frequency in pituitary adenomas warrants further exploration of their potential role in pituitary adenoma treatment and outcome.
    MeSH term(s) Adenoma/diagnostic imaging ; Adenoma/pathology ; Adult ; Aged ; Cohort Studies ; Female ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Nuclear Proteins/metabolism ; Pituitary Neoplasms/metabolism ; Pituitary Neoplasms/pathology ; Prolactin/metabolism ; Transcription Factors/metabolism
    Chemical Substances ARID1A protein, human ; Hypoxia-Inducible Factor 1, alpha Subunit ; Nuclear Proteins ; Transcription Factors ; Prolactin (9002-62-4)
    Language English
    Publishing date 2018-10-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2534351-8
    ISSN 1878-8769 ; 1878-8750
    ISSN (online) 1878-8769
    ISSN 1878-8750
    DOI 10.1016/j.wneu.2018.09.196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: In Vitro Closure Times (PFA-100) Are Different Between Peritoneal Dialysis and Hemodialysis.

    Gokalp, Cenk / Karadag, Fatma Keklik / Braunisch, Matthias Christoph / Schmaderer, Christoph / Gunay, Emrah / Kiper, Hatice Demet / Tobu, Mahmut / Ustün, Celalettin / Demirci, Meltem Sezis / Ozkahya, Mehmet

    Hamostaseologie

    2020  Volume 40, Issue 5, Page(s) 671–678

    Abstract: Introduction:  Platelet dysfunction is not uncommon in patients with end-stage renal disease (ESRD). Type of renal replacement therapy may have an effect on platelet functions, which has not been well investigated. We evaluated in vitro closure time (CT) ...

    Abstract Introduction:  Platelet dysfunction is not uncommon in patients with end-stage renal disease (ESRD). Type of renal replacement therapy may have an effect on platelet functions, which has not been well investigated. We evaluated in vitro closure time (CT) differences between peritoneal dialysis (PD) and hemodialysis (HD) patients using platelet function analyzer (PFA-100)and observed a significant difference between these renal replacement therapies.
    Methods:  Patients with ESRD undergoing PD (
    Results:  Three of 24 (12.5%) PD patients and 16 of 23 (69.5%) HD patients had prolonged PFA-100 Col/EPI,
    Conclusions:  The type of renal replacement therapy may have an effect on in vitro CTs; therefore, studies including more patients with long-term follow-up are needed to investigate if the difference has any impact on clinical outcomes.
    MeSH term(s) Blood Platelets/pathology ; Female ; Humans ; In Vitro Techniques ; Male ; Peritoneal Dialysis/methods ; Platelet Function Tests/methods ; Renal Dialysis/methods
    Language English
    Publishing date 2020-07-27
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 801512-0
    ISSN 2567-5761 ; 0720-9355
    ISSN (online) 2567-5761
    ISSN 0720-9355
    DOI 10.1055/a-1171-0499
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Results of multicenter registry for patients with inherited factor VII deficiency in Turkey.

    Akdeniz, Aydan / Ünüvar, Ayşegül / Ar, Muhlis Cem / Pekpak, Esra / Akyay, Arzu / Mehtap, Özgür / Karadağ, Fatma Keklik / Acıpayam, Can / Doğan, Ali / Ekinci, Ömer / Köker, Sultan Aydın / Albayrak, Canan / Demirci, Ufuk / Güney, Tekin / Kurt, Meltem / Karaman, Serap / Kimyon, Özge Şahin / Albayrak, Sinan / Öncül, Yurday /
    Ünal, Serkan / Şahin, Fahri / Tuna, Rumeysa / Zulfikar, Bulent / Apak, Burcu Belen / Ümit, Elif Gülsüm / Demir, Ahmet Muzaffer

    Scandinavian journal of clinical and laboratory investigation

    2021  Volume 82, Issue 1, Page(s) 28–36

    Abstract: Introduction: Inherited factor VII (FVII) deficiency (FVIID) is the most common of inherited rare bleeding disorders. Other determinants of clinical severity apart from FVII level (FVIIL) include genetic and environmental factors. We aimed to identify ... ...

    Abstract Introduction: Inherited factor VII (FVII) deficiency (FVIID) is the most common of inherited rare bleeding disorders. Other determinants of clinical severity apart from FVII level (FVIIL) include genetic and environmental factors. We aimed to identify the cut-off FVIILs for general and severe bleedings in patients with FVIID by using an online national registry system including clinical, laboratory, and demographic characteristics of patients.
    Methods: Demographic, clinical, and laboratory data of patients with FVIID extracted from the national database, constituted by the Turkish Society of Hematology, were examined. Bleeding phenotypes, general characteristics, and laboratory features were assessed in terms of FVIILs. Bleeding rates and prophylaxis during special procedures/interventions were also recorded.
    Results: Data from 197 patients showed that 46.2% of patients had FVIIL< 10%. Most bleeds were of mucosal origin (67.7%), and severe bleeds tended to occur in younger patients (median age: 15 (IQR:6-29)). Cut-off FVIILs for all and severe bleeds were 16.5% and 7.5%, respectively. The major reason for long-term prophylaxis was observed as central nervous system bleeding (80%).
    Conclusion: Our data are consistent with most of the published literature in terms of cut-off FVIIL for bleeding, as well as reasons for prophylaxis, showing both an increased severity of bleeding and younger age at diagnosis with decreasing FVIIL. However, in order to offer a classification similar to that in Hemophilia A or B, data of a larger cohort with information about environmental and genetic factors are required.
    MeSH term(s) Blood Coagulation Disorders, Inherited ; Factor VII/therapeutic use ; Factor VII Deficiency/diagnosis ; Factor VII Deficiency/drug therapy ; Factor VII Deficiency/genetics ; Hemorrhage/prevention & control ; Humans ; Registries ; Turkey/epidemiology
    Chemical Substances Factor VII (9001-25-6)
    Language English
    Publishing date 2021-12-16
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 3150-1
    ISSN 1502-7686 ; 0036-5513
    ISSN (online) 1502-7686
    ISSN 0036-5513
    DOI 10.1080/00365513.2021.2013524
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: In Vitro Closure Times (PFA-100) Are Different Between Peritoneal Dialysis and Hemodialysis

    Gokalp, Cenk / Karadag, Fatma Keklik / Braunisch, Matthias Christoph / Schmaderer, Christoph / Gunay, Emrah / Kiper, Hatice Demet / Tobu, Mahmut / Ustün, Celalettin / Demirci, Meltem Sezis / Ozkahya, Mehmet

    Hämostaseologie

    2020  Volume 40, Issue 05, Page(s) 671–678

    Abstract: Introduction: Platelet dysfunction is not uncommon in patients with end-stage renal disease (ESRD). Type of renal replacement therapy may have an effect on platelet functions, which has not been well investigated. We evaluated in vitro closure time (CT) ...

    Abstract Introduction: Platelet dysfunction is not uncommon in patients with end-stage renal disease (ESRD). Type of renal replacement therapy may have an effect on platelet functions, which has not been well investigated. We evaluated in vitro closure time (CT) differences between peritoneal dialysis (PD) and hemodialysis (HD) patients using platelet function analyzer (PFA-100)and observed a significant difference between these renal replacement therapies.
    Methods: Patients with ESRD undergoing PD ( n  = 24) or HD ( n  = 23) for more than 6 months were included. Blood samples for collagen/epinephrine (Col/EPI) and collagen/adenosine diphosphate (Col/ADP) measurements were obtained before HD at a mid-week session for HD patients and at an outpatient control time for PD patients.
    Results: Three of 24 (12.5%) PD patients and 16 of 23 (69.5%) HD patients had prolonged PFA-100 Col/EPI, p < 0.001. Likewise, 4.2% of PD patients and 87.0% of HD patients had prolonged PFA-100 Col/ADP, p < 0.001. Moreover, the median times of PFA-Col/EPI and PFA-100 Col/ADP were significantly lower in PD patients compared with those of HD patients ( p < 0.001). Multivariate analysis showed that the type of renal replacement was a risk factor for both elevated PFA-100 Col/ADP and PFA-100 Col/EPI after adjusted for platelets, hematocrit, and urea ( p < 0.001).
    Conclusions: The type of renal replacement therapy may have an effect on in vitro CTs; therefore, studies including more patients with long-term follow-up are needed to investigate if the difference has any impact on clinical outcomes.
    Keywords in vitro closure time ; hemodialysis ; peritoneal dialysis ; thrombocyte function ; primary hemostasis ; in vitro Verschlusszeit ; Hämodialyse ; Peritonealdialyse ; Thrombozytenfunktion ; primäreHämostase
    Language English
    Publishing date 2020-07-27
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 801512-0
    ISSN 2567-5761 ; 0720-9355
    ISSN (online) 2567-5761
    ISSN 0720-9355
    DOI 10.1055/a-1171-0499
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article: Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis.

    Karadag, Fatma Keklik / Yenerel, Mustafa Nuri / Yılmaz, Mehmet / Uskudar, Hava / Ozkocaman, Vildan / Tuglular, Tülin Firatli / Erdem, Fuat / Unal, Ali / Ayyildiz, Orhan / Ozet, Gülsüm / Comert, Melda / Kaya, Emin / Ayer, Mesut / Salim, Ozan / Guvenc, Birol / Ozdogu, Hakan / Mehtap, Özgur / Sonmez, Mehmet / Guler, Nil /
    Hacioglu, Sibel / Aydogdu, İsmet / Bektas, Ozlen / Toprak, Selami Kocak / Kaynar, Lale / Yagci, Munci / Aksu, Salih / Tombak, Anil / Karakus, Volkan / Yavasoglu, İrfan / Onec, Birgul / Ozcan, Mehmet Ali / Undar, Levent / Ali, Rıdvan / Ilhan, Osman / Saydam, Guray / Sahin, Fahri

    American journal of blood research

    2021  Volume 11, Issue 3, Page(s) 279–285

    Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of ...

    Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.
    Language English
    Publishing date 2021-06-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2620435-6
    ISSN 2160-1992
    ISSN 2160-1992
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top